Autonomous Vehicle Contactless Sample Collection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The transmission of infectious diseases in medical environments poses a significant risk due to the ubiquity of infectious organisms, which can lead to infections among patients and medical personnel, highlighting the need for effective disease detection and diagnosis methods that minimize exposure and contact.

Innovation Solution

A method utilizing unmanned autonomous vehicles to provide collection devices to subjects, obtain samples, and deliver them to examination centers for analysis, enabling contactless disease detection and diagnosis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If patients travel to medical offices for diagnosis and treatment, then disease detection and diagnosis can be performed, but transmission of infectious diseases occurs exposing patients and medical personnel to infection risks

Engineering Contradiction:
Improvedisease detection capabilityVSAvoidinfection transmission risk
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces an autonomous vehicle as an intermediary to transport collection devices between patients and examination centers. This mediator eliminates direct human contact during sample collection and transport, thereby preventing infection transmission while maintaining disease detection capability. The autonomous vehicle serves as a safe bridge that connects the patient's environment with the medical examination facility without requiring patients to physically visit the facility.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Measurement precision

If medical personnel directly collect samples from patients, then accurate disease diagnosis can be obtained, but direct contact increases the risk of infection for medical personnel

Engineering Contradiction:
Improvediagnosis accuracyVSAvoidinfection risk to medical personnel
Core Design Contradiction:
Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The patent enables patients to perform self-collection of biological samples using collection devices provided by the autonomous vehicle. Patients can independently collect their own samples (such as saliva, nasal swabs, or blood) without requiring medical personnel's direct involvement. This self-service approach maintains sample quality for accurate diagnosis while completely eliminating the infection risk to medical personnel that would result from direct contact during sample collection.

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The autonomous vehicle acts as an intermediary that delivers collection devices to patients and retrieves completed samples for transport to examination centers. This mediator system allows diagnosis to be performed accurately through proper sample collection and handling, while preventing medical personnel from having direct contact with potentially infectious patients during the sample collection process.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If traditional in-person medical consultations are conducted, then comprehensive patient evaluation can be performed, but it increases transmission spread of contagions in the community

Engineering Contradiction:
Improvepatient evaluation qualityVSAvoidcontagion transmission spread
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent divides the traditional in-person medical consultation process into separate segments: sample collection at the patient's location (via autonomous vehicle delivery) and laboratory analysis at the examination center. This segmentation allows comprehensive patient evaluation to be performed through remote sample analysis without requiring the patient to travel to or interact with medical facilities, thereby maintaining diagnostic quality while preventing community-wide contagion spread.

Inventive Principle:
Principle #1Segmentation

Data Source

PatentUS20220161251A1Contactless detection of an aberrant condition
Publication Date: 2022.05.26 SINGULAR GENOMICS SYSTEMS INC
  • US20220161251A1 patent drawing
  • US20220161251A1 patent drawing
  • US20220161251A1 patent drawing

AI summary

Disclosed herein, inter alfa, are systems and methods for contactless evaluation of a biological sample.